Computational details

Let:

Yijkt be the response of subject j in sequence i at time t with treatment k.

Phoenix_UserDocs_Bioequivalence_Object_image1671 be a vector of responses for subject j in sequence i. The components of Y are arranged in the ascending order of time.

Phoenix_UserDocs_Bioequivalence_Object_image1673.be the design vector of treatment T in sequence i.

Phoenix_UserDocs_Bioequivalence_Object_image1675 be a design vector for treatment R in sequence i.

ni > 1 be the number of subjects in sequence i.

Assume the mean responses of Phoenix_UserDocs_Bioequivalence_Object_image1677, follow a linear model:

Phoenix_UserDocs_Bioequivalence_Object_image1679

where mT, mR are the population mean responses of Y with treatments T and R respectively, and Xi are design/model matrices.

Let:

Phoenix_UserDocs_Bioequivalence_Object_image1681

be the number of occasions T is assigned to the subjects in sequence i.

Phoenix_UserDocs_Bioequivalence_Object_image1683

be the number of occasions R is assigned to the subjects in sequence i.

Then:

Phoenix_UserDocs_Bioequivalence_Object_image1685

Assume that the covariances:

Phoenix_UserDocs_Bioequivalence_Object_image1687

follow the model:

Phoenix_UserDocs_Bioequivalence_Object_image1689

where the parameters:

Phoenix_UserDocs_Bioequivalence_Object_image1691

are defined as follows:

Phoenix_UserDocs_Bioequivalence_Object_image1693

intra-subject correlation coefficients are:

Phoenix_UserDocs_Bioequivalence_Object_image1695

intra-subject covariances are:

Phoenix_UserDocs_Bioequivalence_Object_image1697

intra-subject variances are:

Phoenix_UserDocs_Bioequivalence_Object_image1699

For PBE and IBE investigations, it is useful to define additional parameters:

Phoenix_UserDocs_Bioequivalence_Object_image1701

Except for sD*, all the quantities above are non-negative when they exist. It satisfies the equation:

Phoenix_UserDocs_Bioequivalence_Object_image1703

In general, this sD* may be negative. This method for PBE/IBE is based on the multivariate model. This method is applicable to a variety of higher-order two-treatment crossover designs including TR/RT/TT/RR (the Balaam Design), TRT/RTR, or TxRR/xRTT/RTxx/TRxx/xTRR/RxTT (Table 5.7 of Jones and Kenward, page 205).

Given the ith sequence, let:

Phoenix_UserDocs_Bioequivalence_Object_image1705

where:

Phoenix_UserDocs_Bioequivalence_Object_image1707 is the sample mean of the ith sequence.

Vi is the within-sequence sample covariance matrix.

It can be shown that:

Phoenix_UserDocs_Bioequivalence_Object_image1709

Furthermore, it can be shown that {SiT, SiR} (for PBE) are statistically independent from {D} and {SiWT, SiWR}, and that the four statistics D, SiI, SiWT, SiWR (for IBE) are statistically independent.

Let ai be sets of normalized weights, chosen to yield the method of moments estimates of the h. Then define the estimators of the components of the linearized criterion by:

Phoenix_UserDocs_Bioequivalence_Object_image1711

Phoenix_UserDocs_Bioequivalence_Object_image1713

Phoenix_UserDocs_Bioequivalence_Object_image1715

Phoenix_UserDocs_Bioequivalence_Object_image1717

Using the above notation, one may define unbiased moment estimators for the PBE criteria:

Phoenix_UserDocs_Bioequivalence_Object_image1719

and for the IBE criteria:

Phoenix_UserDocs_Bioequivalence_Object_image1721

Construct a 95% upper bound for h based on the TRTR/RTRT design using Howe’s approximation I and a modification proposed by Hyslop, Hsuan and Holder (2000). This can be generalized to compute the following sets of nq, H, and U statistics:

Phoenix_UserDocs_Bioequivalence_Object_image1723

where the degrees of freedom nq are computed using Satterthwaite’s approximation. Then, the 95% upper bound for each h is:

Phoenix_UserDocs_Bioequivalence_Object_image1725

If Hq < 0, that indicates bioequivalence; Hq > 0 fails to show bioequivalence.


Legal Notice | Contact Certara
© Certara USA, Inc. All rights reserved.